Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes

Advances in Therapy

Volumn 22, Issue 6, 2005, Pages 527-542

  Bevilacqua, Maurizio ^a   Righini, Velella ^a   Barrella, Massimo ^a   Vago, Tarcisio ^a   Chebat, Enrica ^a   Dominguez, Ligia J ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

ApoA I; ApoB; Fluvastatin XL; HDL; LDL; Simvastatin; Small, dense LDL; Triglycerides; Type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; GLIBENCLAMIDE; GLIMEPIRIDE; HIGH DENSITY LIPOPROTEIN; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN GLARGINE; LIPID; LOW DENSITY LIPOPROTEIN; METFORMIN; MINERAL; SIMVASTATIN; TRIACYLGLYCEROL; VITAMIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET; FEMALE; HEALTH PROGRAM; HUMAN; HYPERTRIGLYCERIDEMIA; LIFESTYLE; LIPID TRIAD; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SLOW DRUG RELEASE;

EID: 33645022024     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02849947     Document Type: Article

References (145)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
2. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124:136-145.
3. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes. 1997;46:1354-1359.
4. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
5. Miettinen H, Lehto S, Salomaa V, et al, for the FINMONICA Myocardial Infarction Register Study Group. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care. 1998;21:69-75.
6. Vaccaro O, Stamler J, Neaton JD. Sixteen-year coronary mortality in black and white men with diabetes screened for the Multiple Risk Factor Intervention Trial (MRFIT). Int J Epidemiol. 1998;27:636-641.
7. Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med. 2001;249:225-235.
8. Serrano Rios M. Epidemiology of cardiovascular disease in type 2 diabetes. Int J Clin Pract. 2001; (suppl):4-7.
9. Sowers JR. Update on the cardiometabolic syndrome. Clin Cornerstone. 2001;4:17-23.
10. Taskinen MR. Diabetic dyslipidemia. Atheroscler Suppl. 2002;3:47-51.
11. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46:733-749.
12. Vaccaro O, Eberly LE, Neaton JD, Yang L, Riccardi G, Stamler J. Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Arch Intern Med. 2004;164:1438-1443.
13. Temelkova-Kurktschiev T, Hanefeld M. The lipid triad in type 2 diabetes-prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. Exp Clin Endocrinol Diabetes. 2004;112:75-79.
14. Drexel H, Aczel S, Marte T, et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care. 2005;28:101-107.
15. Allayee H, Dominguez KM, Aouizerat BE, et al. Contribution of the hepatic lipase gene to the atherogenic lipoprotein phenotype in familial combined hyperlipidemia. J Lipid Res. 2000;41:245-252.
16. Austin MA. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep. 2000;2:200-207.
17. Betteridge DJ. Diabetic dyslipidaemia. Diabetes Obes Metab. 2000;2(suppl 1):S31-S36.
18. Boquist S, Hamsten A, Karpe F, Ruotolo G. Insulin and non-esterified fatty acid relations to alimentary lipaemia and plasma concentrations of postprandial triglyceride-rich lipoproteins in healthy middle-aged men. Diabetologia. 2000;43:185-193.
19. Gervaise N, Garrigue MA, Lasfargues G, Lecomte P. Triglycerides, apo C3 and Lp B: C3 and cardiovascular risk in type II diabetes. Diabetologia. 2000;43:703-708.
20. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk. 2000;7:325-331.
21. Rader DJ, Jaye M. Endothelial lipase: a new member of the triglyceride lipase gene family. Curr Opin Lipidol. 2000;11:141-147.
22. Adeli K, Taghibiglou C, Van Iderstine SC, Lewis GF. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med. 2001;11:170-176.
23. Demant T. Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects. Fortschr Med Orig. 2001;119:37-40.
24. Frenais R, Nazih H, Ouguerram K, et al. In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus. J Clin Endocrinol Metab. 2001;86:1962-1967.
25. Erkelens DW. Insulin resistance syndrome and type 2 diabetes mellitus. Am J Cardiol. 2001;88:38J-42J.
26. Guerin M, Le Goff W, Lassel TS, Van Tol A, Steiner G, Chapman MJ. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol. 2001;21:282-288.
27. Huuskonen J, Olkkonen VM, Jauhiainen M, Ehnholm C. The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis. 2001;155:269-281.
28. Malloy MJ, Kane JP. A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv Intern Med. 2001;47:111-136.
29. Riemens SC, van Tol A, Scheek LM, Dullaart RP. Plasma cholesteryl ester transfer and hepatic lipase activity are related to high-density lipoprotein cholesterol in association with insulin resistance in type 2 diabetic and non-diabetic subjects. Scand J Clin Lab Invest. 2001;61:1-9.
30. Rubies-Prat J, Ordonez-Llanos J, Martin S, et al. Low-density lipoprotein particle size, triglyceride-rich lipoproteins, and glucose tolerance in non-diabetic men with essential hypertension. Clin Exp Hypertens. 2001;23:489-500.
31. Taskinen MR. Pathogenesis of dyslipidemia in type 2 diabetes. Exp Clin Endocrinol Diabetes. 2001;109(suppl 2):S180-S188.
32. Zimmermann R, Panzenbock U, Wintersperger A, et al. Lipoprotein lipase mediates the uptake of glycated LDL in fibroblasts, endothelial cells, and macrophages. Diabetes. 2001;50:1643-1653.
33. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-2581.
34. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43:1363-1379.
35. Florkowski CM. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones. Am J Cardiovasc Drugs. 2002;2:15-21.
36. Frayn KN. Adipose tissue as a buffer for daily lipid flux. Diabetologia. 2002;45:1201-1210.
37. Murdoch SJ, Carr MC, Kennedy H, Brunzell JD, Albers JJ. Selective and independent associations of phospholipid transfer protein and hepatic lipase with the LDL subfraction distribution. J Lipid Res. 2002;43:1256-1263.
38. Ohmura H, Mokuno H, Sawano M, et al. Lipid compositional differences of small, dense low-density lipoprotein particle influence its oxidative susceptibility: possible implication of increased risk of coronary artery disease in subjects with phenotype B. Metabolism. 2002;51:1081-1087.
39. Reusch JE. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol. 2002;90:19G-26G.
40. Rodrigo E, Gonzalez-Lamuno D, Ruiz JC, et al. Apolipoprotein C-III and E polymorphisms and cardiovascular syndrome, hyperlipidemia, and insulin resistance in renal transplantation. Am J Transplant. 2002;2:343-348.
41. Ruotolo G, Howard BV. Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep. 2002;4:494-500.
42. Sniderman AD, Lamarche B, Tilley J, Seccombe D, Frohlich J. Hypertriglyceridemic hyperapo B in type 2 diabetes. Diabetes Care. 2002;25:579-582.
43. Talmud PJ, Hawe E, Robertson K, Miller GJ, Miller NE, Humphries SE. Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle-aged men. Ann Hum Genet. 2002;66:111-124.
44. Yoshino G, Hirano T, Kazumi T. Atherogenic lipoproteins and diabetes mellitus. J Diabetes Complications. 2002;16:29-34.
45. Ayyobi AF, McGladdery SH, McNeely MJ, Austin MA, Morulsky AG, Brunzell JD. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2003;23:1289-1294.
46. Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellirus, and familial combined hyperlipidemia. Am J Cardiol. 2003;92:27J-33J.
47. Brundert M, Heeren J, Greten H, Rinninger F. Hepatic lipase mediates an increase in selective uptake of HDL-associated cholesteryl esters by cells in culture independent from SR-BI. J Lipid Res. 2003;44:1020-1032.
48. Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med. 2003;115(suppl 8A):24S-28S.
49. Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol 2003;14:347-352.
50. Chadarevian R, Foubert L, Beucler I, et al. Lipoprotein lipase activity and common gene variants in severely hypertriglyceridemic patients with and without diabetes. Horm Res. 2003;60:61-67.
51. Deeb SS, Zambon A, Carr MC, Ayyobi AF, Brunzell JD. Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. J Lipid Res. 2003;44:1279-1286.
52. Duong M, Psaltis M, Rader DJ, Marchadier D, Barter PJ, Rye KA. Evidence that hepatic lipase and endothelial lipase have different substrate specificities for high-density lipoprotein phospholipids. Biochemistry. 2003;42:13778-13785.
53. Erbas T. Metabolic syndrome. Acta Diabetol. 2003;40(suppl 2):S401-S404.
54. Eschwege E. The dysmetabolic syndrome, insulin resistance and increased cardiovascular (CV) morbidity and mortality in type 2 diabetes: aetiological factors in the development of CV complications. Diabetes Metab. 2003;29:6S19-6S27.
55. Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab. 2003;5(suppl 1):S19-S27.
56. LaMonte MJ, Ainsworth BE, DuBose KD, et al. The hypertriglyceridemic waist phenotype among women. Atherosclerosis. 2003;171:123-130.
57. Le NA. Small, dense low-density lipoprotein: risk or myth? Curr Atheroscler Rep. 2003;5:22-28.
58. Lee W, Min WK, Chun S, et al. Low-density lipoprotein subclass and its correlating factors in diabetics. Clin Biochem. 2003;36:657-661.
59. Lee SJ, Moye LA, Campos H, Williams GH, Sacks FM. Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease. Atherosclerosis. 2003;167:293-302.
60. Maruyama C, Imamura K, Teramoto T. Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb. 2003;10:186-191.
61. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans. 2003;31:1066-1069.
62. Rader DJ. Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol. 2003;92:42J-49J.
63. Rashid S, Watanabe T, Sakaue T, Lewis GF. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem. 2003;36:421-429.
64. Schlitt A, Bickel C, Thumma P, et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 2003;23:1857-1862.
65. Skoglund-Andersson C, Ehrenborg E, Fisher RM, Olivecrona G, Hamsten A, Karpe F. Influence of common variants in the CETP, LPL, HL and APO E genes on LDL heterogeneity in healthy, middle-aged men. Atherosclerosis. 2003;167:311-317.
66. Soro A, Jauhiainen M, Ehnholm C, Taskinen MR. Determinants of low HDL levels in familial combined hyperlipidemia. J Lipid Res. 2003;44:1536-1544.
67. Takahashi T, Hirano T, Okada K, Adachi M. Apolipoprotein CIII deficiency prevents the development of hypertriglyceridemia in streptozotocin-induced diabetic mice. Metabolism. 2003;52:1354-1359.
68. Tan KC, Shiu SW, Wong Y. Plasma phospholipid transfer protein activity and small, dense LDL in type 2 diabetes mellitus. Eur J Clin Invest. 2003;33:301-306.
69. Taskinen MR. LDL-cholesterol, HDL-cholesterol or triglycerides - which is the culprit? Diabetes Res Clin Pract. 2003;61(suppl 1):S19-S26.
70. Watson KE, Horowitz BN, Matson G. Lipid abnormalities in insulin resistant states. Rev Cardiovasc Med. 2003;4:228-236.
71. Williams PT, Superko HR, Haskell WL, et al. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol. 2003;23:314-321.
72. Zambon A, Deeb SS, Pauletto P, Crepaldi G, Brunzell JD. Hepatic lipase: a marker for cardiovascular disease risk and response to therapy. Curr Opin Lipidol. 2003;14:179-189.
73. Zambon A, Bertocco S, Vitturi N, Polentarutti V, Vianello D, Crepaldi G. Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins. Biochem Soc Trans. 2003;31:1070-1074.
74. Badellino KO, Rader DJ. The role of endothelial lipase in high-density lipoprotein metabolism. Curr Opin Cardiol. 2004;19:392-395.
75. Broedl UC, Maugeais C, Millar JS, et al. Endothelial lipase promotes the catabolism of ApoB-containing lipoproteins. Circ Res. 2004;94:1554-1561.
76. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab. 2004;89:2601-2607.
77. Caslake MJ, Packard CJ. Phenotypes, genotypes and response to statin therapy. Curr Opin Lipidol. 2004;15:387-392.
78. Cziraky MJ. Management of dyslipidemia in patients with metabolic syndrome. J Am Pharm Assoc. 2004;44:478-488.
79. Hirano T, Ito Y, Koba S, et al. Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol. 2004;24:558-563.
80. Hirano T, Ito Y, Koba S, et al. Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol. 2004;24:558-563.
81. Ishida T, Choi SY, Kundu RK, et al. Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice. J Biol Chem. 2004;279:45085-45092.
82. Jansen H. Hepatic lipase: friend or foe and under what circumstances? Curr Atheroscler Rep. 2004;6:343-347.
83. Jaye M, Krawiec J. Endothelial lipase and HDL metabolism. Curr Opin Lipidol. 2004;15:183-189.
84. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27:1496-1504.
85. Marcil M, O'Connell B, Krimbou L, Genest J Jr. High-density lipoproteins: multifunctional vanguards of the cardiovascular system. Expert Rev Cardiovasc Ther. 2004;2:417-430.
86. Pi-Sunyer FX. The epidemiology of central fat distribution in relation to disease. Nutr Rev. 2004;62:5120-5126.
87. Rohrer L, Hersberger M, von Eckardstein A. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol. 2004;15:269-278.
88. Williams CM, Maitin V, Jackson KG. Triacylglycerol-rich lipoprotein-gene interactions in endothelial cells. Biochem Soc Trans. 2004;32:994-998.
89. Jahangiri A, Rader DJ, Marchadier D, Curtiss LK, Bonnet DJ, Rye KA. Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. J Lipid Res. 2005;46:896-903.
90. St-Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005;25:553-559.
91. Jokubaitis LA. Updated clinical safety experience with fluvastatin. Am J Cardiol. 1994;73:18D-24D.
92. Tomlinson B, Mak TW, Tsui JY, et al. Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia. Am J Cardiol. 1995;76:136A-139A.
93. Foldes K, Maklary E, Vargha P, et al. Effect of diet and fluvastatin treatment on the serum lipid profile of kidney transplant, diabetic recipients: a 1-year follow up. Transpl Int. 1998;11(suppl 1): S65-S68.
94. Olsson AG, Pauciullo P, Soska V, et al. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial. Clin Ther. 2001;23:45-61.
95. Sonmez A, Baykal Y, Kilic M, et al. Fluvastatin improves insulin resistance in nondiabetic dyslipidemic patients. Endocrine. 2003;22:151-154.
96. Guan JZ, Murakami H, Yamato K, et al. Effects of fluvastatin in type 2 diabetic patients with hyperlipidemia: reduction in cholesterol oxidation products and VCAM-1. J Atheroscler Thromb. 2004;11:56-61.
97. Bevilacqua M, Bettica P, Milani M, et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol. 1997;79:84-87.
98. Bevilacqua M, Guazzini B, Righini V, Barrella M, Toscano R, Chebat E. Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded end-point (PROBE) trial. Curr Ther Res. 2004;65:330-344.
99. Yuan JN, Tsai MY, Hegland J, Hunninghake DB. Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis. 1991;87:147-157.
100. Marz W, Scharnagl H, Abletshauser C, et al. Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation. 2001;103:1942-1948.
101. Winkler K, Abletshauser C, Hoffmann MM, et al. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab. 2002;87:5485-5490.
102. Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, Marz W. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab. 2004;89:1153-1159.
103. Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N. Fluvastatin improves endothelial dysfunction in overweight postmenopausal women through small dense low-density lipoprotein reduction. Metabolism. 2004;53:733-739.
104. Daubresse JC, Machowski R, Pulinx E. Efficacy of simvastatin for lowering cholesterol in non-insulin dependent diabetic patients with hypercholesterolemia. Acta Clin Belg. 1994;49:68-75.
105. Farrer M, Winocour PH, Evans K, et al. Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures. Diabetes Res Clin Pract. 1994;23:111-119.
106. Jeck T, Riesen WF, Keller U. Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM. Diabet Med. 1997;14:564-570.
107. Illingworth DR, Grouse JR III, Hunninghake DB, et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 2001;17:43-50.
108. Hunninghake DB, Ballantyne CM, Maccubbin DL, Shah AK, Gumbiner B, Mitchel YB. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clin Ther. 2003;25:1670-1686.
109. Feldman T, Koren M, Insull W Jr, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol. 2004;93:1481-1486.
110. Isaacsohn J, Hunninghake D, Schrott H, et al. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol. 2003;26:18-24.
111. Lewin AJ, Kipnes MS, Meneghini LF, et al. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2004;26:379-389.
112. Ballantyne CM, Blazing MA, Hunninghake DB, et al. Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J. 2003;146:862-869.
113. Miller M, Dobs A, Yuan Z, Battisti WP, Borisute H, Palmisano J. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. Curr Med Res Opin. 2004;20:1087-1094.
114. Steyn K, Weich HF, Bonnici F, et al. Simvastatin in non-insulin-dependent diabetic patients with hypercholesterolaemia. S Afr Med J. 1992;82:402-406.
115. Hommel E, Andersen P, Gall MA, et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia. 1992;35:447-451.
116. Sartor G, Katzman P, Eizyk E, et al. Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus. Int J Clin Pharmacol Ther. 1995;33:3-6.
117. Tikkanen MJ, Laakso M, Ilmonen M, et al. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. Diabetes Care. 1998;21:477-481.
118. Tomas M, Senti M, Garcia-Faria F, et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2000;20:2113-2119.
119. Insull W, Kafonek S, Goldner D, Zieve F (ASSET Investigators). Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks. Am J Cardiol. 2001;87:554-559.
120. Geiss HC, Schwandt P, Parhofer KG. Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia. Exp Clin Endocrinol Diabetes. 2002;110:182-187.
121. Geiss HC, Parhofer KG, Schwandt P. Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis. J Intern Med. 1999;245:47-55.
122. van Tits LJ, Smilde TJ, van Wissen S, de Graaf J, Kastelein JJ, Stalenhoef AF. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia. J Investig Med. 2004;52:177-184.
123. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective randomized open blinded end-point. Blood Press. 1992;1:113-119.
124. Lindholm LH, Hansson L, Dahlof B, et al. The Swedish Trial in old patients with hypertension-2 (STOP-hypertension-2): a progress report. Blood Press. 1996;5:300-304.
125. Hansson L, Hedner T, Lindholm L, et al. The Captopril Prevention Project (CAPPP) in hypertension-baseline data and current status. Blood Press. 1997;6:365-367.
126. Nauck M, Marz W, Haas B, Wieland H. Homogeneous assay for direct determination of high-density lipoprotein cholesterol evaluated. Clin Chem. 1996;42:424-429.
127. Tamasawa N, Matsui J, Ogawa Y, et al. Effect of doxazosin on the size of LDL particle in the type 2 diabetic patients with hypertension. J Diabetes Complications. 2000;14:135-139.
128. Hoefner DM, Hodel SD, O'Brien JF, et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL system. Clin Chem. 2001;47:266-274.
129. Matsui J, Tamasawa N, Tanabe J, et al. LDL particle size and lipid composition are risk factors for microalbuminuria in normotensive and normocholesterolemic patients with type 2 diabetes. Diabetes Res Clin Pract. 2004;66:229-236.
130. Knopp RH, Frolich JJ. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia: preliminary report. Am J Cardiol. 1994;73:39D-41D.
131. Mauger JF, Couture P, Paradis ME, Lamarche B. Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men. Atherosclerosis. 2005;178:157-163.
132. Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. Am J Cardiol. 1995;76:129A-135A.
133. Cheung MC, Sibley SD, Palmer JP, Oram JF, Brunzell JD. Lipoprotein lipase and hepatic lipase: their relationship with HDL subspecies Lp(A-I) and Lp(A-I,A-II). J Lipid Res. 2003;44:1552-1558.
134. Zambon A, Deeb SS, Brown BG, Hokanson JE, Brunzell JD. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation. 2001;103:792-798.
135. Zambon A, Deeb SS, Hokanson JE, Brown BG, Brunzell JD. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler Thromb Vasc Biol. 1998;18:1723-1729.
136. Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation. 1999;99:1959-1964.
137. Borggreve SE, De Vries R, Dullaart RP. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest. 2003;33:1051-1069.
138. de Vries R, Borggreve SE, Dullaart RP. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. Clin Lab. 2003;49:601-613.
139. Hansel B, Kontush A, Twickler MT. High-density lipoprotein as a key component in the prevention of premature atherosclerotic disease in the insulin resistance syndrome. Semin Vasc Med. 2004;4:215-223.
140. Deslypere JP. Clinical implications of the biopharmaceutical properties of fluvastatin. Am J Cardiol. 1994;73:12D-17D.
141. Barilla D, Prasad P, Hubert M, Gumbhir-Shah K. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL. Biopharm Drug Dispos. 2004;25:51-59.
142. Corsini A. The use of statins in optimising reduction of cardiovascular risk: focus on fluvastatin. Int J Clin Pract. 2004;58:494-503.
143. Schoonjans K, Peinado-Onsurbe J, Fruchart JC, Tailleux A, Fievet C, Auwerx J. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett. 1999;452:160-164.
144. Bard JM, Dallongeville J, Hagen E, et al. Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition. Metabolism. 1995;44:1447-1454.
145. Verd JC, Peris C, Alegret M, et al. Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits. Br J Pharmacol. 1999;127:1479-1485.